Treatments information after T315I mutation detection (n = 216)
| Treatment . | n (%) . | Median duration, mo (range) . | New treatment, n (%)* . | Carry-over, n (%)* . | By line of treatment†, n (%) . | |||
|---|---|---|---|---|---|---|---|---|
| First line (n = 216) . | Second line (n = 151) . | Third line (n = 97) . | Four or more lines (n = 60) . | |||||
| Second-generation TKI | 125 (58) | 1.3 (0.1-32.1) | 67 (31) | 58 (27) | 88 (41) | 34 (23) | 15 (15) | 23 (38) |
| Hydroxyurea | 87 (40) | 1.8 (0.1-34.9) | 74 (34) | 13 (6) | 38 (18) | 50 (33) | 25 (26) | 47 (78) |
| Imatinib | 78 (36) | 1.3 (0.1-83.5) | 28 (13) | 50 (23) | 72 (33) | 9 (6) | 9 (9) | 16 (27) |
| Cytarabine | 57 (26) | 0.3 (0.1-22.9) | 57 (26) | 0 | 13 (6) | 31 (21) | 18 (19) | 37 (62) |
| Stem cell transplantation | 37 (17) | N/A | 37 (17) | 0 | N/A | N/A | N/A | N/A |
| MK-0457 | 25 (12) | 1.6 (0.1-13.2) | 25 (12) | 0 | 1 (0.5) | 8 (5) | 6 (6) | 15 (25) |
| Other investigational drug | 26 (12) | 6.8 (0.2-27.6) | 24 (11) | 2 (1) | 5 (2) | 9 (6) | 6 (6) | 15 (25) |
| Interferon-α | 14 (6) | 4.1 (0.1-34.9) | 12 (5) | 2 (1) | 2 (1) | 4 (3) | 6 (6) | 3 (5) |
| Treatment . | n (%) . | Median duration, mo (range) . | New treatment, n (%)* . | Carry-over, n (%)* . | By line of treatment†, n (%) . | |||
|---|---|---|---|---|---|---|---|---|
| First line (n = 216) . | Second line (n = 151) . | Third line (n = 97) . | Four or more lines (n = 60) . | |||||
| Second-generation TKI | 125 (58) | 1.3 (0.1-32.1) | 67 (31) | 58 (27) | 88 (41) | 34 (23) | 15 (15) | 23 (38) |
| Hydroxyurea | 87 (40) | 1.8 (0.1-34.9) | 74 (34) | 13 (6) | 38 (18) | 50 (33) | 25 (26) | 47 (78) |
| Imatinib | 78 (36) | 1.3 (0.1-83.5) | 28 (13) | 50 (23) | 72 (33) | 9 (6) | 9 (9) | 16 (27) |
| Cytarabine | 57 (26) | 0.3 (0.1-22.9) | 57 (26) | 0 | 13 (6) | 31 (21) | 18 (19) | 37 (62) |
| Stem cell transplantation | 37 (17) | N/A | 37 (17) | 0 | N/A | N/A | N/A | N/A |
| MK-0457 | 25 (12) | 1.6 (0.1-13.2) | 25 (12) | 0 | 1 (0.5) | 8 (5) | 6 (6) | 15 (25) |
| Other investigational drug | 26 (12) | 6.8 (0.2-27.6) | 24 (11) | 2 (1) | 5 (2) | 9 (6) | 6 (6) | 15 (25) |
| Interferon-α | 14 (6) | 4.1 (0.1-34.9) | 12 (5) | 2 (1) | 2 (1) | 4 (3) | 6 (6) | 3 (5) |
Only the major treatments are summarized in this table. If the start date of the drug is before T315I mutation detection, it is called “carry-over”; if the start date of the drug is after T315I mutation detection, it is called “new treatment.”
A single drug can be used as monotherapy or combined with other drugs and can be used in multiple lines of therapies. Therefore, the total of first- to fourth-line treatments with a drug may be greater than 100%.